MNKD Investors

Technosphere®

One of the largest organs in your body are the lungs. Picture the size of a full tennis court and that is roughly the surface area of both lungs in a typical adult.

read more
NTM Lung Disease on the Rise

“I cough every morning upon waking, so I don’t feel rested.” “Imagine not being able to breathe.” “Anxiety ruins everything about you – it’s not a normal life.” “You just exist from day to day and week to week.”

read more

What exactly is the Technosphere® Platform?

One of the largest organs in your body are the lungs. Picture the size of a full tennis court and that is roughly the surface area of both lungs in a typical adult. Running through those lungs are airways whose total length measures 1,500 miles – that’s the distance between Chicago and Las Vegas, New York to Albuquerque, and Los Angeles to Nashville.

Simply put, the lungs create a wonderful platform for effective drug delivery. MannKind’s Technosphere technology recognizes this and provides the distinct advantage of rapid, deep lung drug delivery. The effect is similar to intravenous delivery (I.V.; within a vein) and has the added benefit of bypassing the liver which can be especially helpful in reducing systemic side effects.

Examining it closer, it helps to look at inhalation, air flow travel, and the exhale. When you breathe in, air is drawn into the lung and flows down curving, narrowing airways that end in the air sacs or alveoli. When air is exhaled, the flow is reversed. Between the end of an inhalation and the start of exhalation, the air in the lung is stationary. To reach the deep lung, inhaled particles must be carried by the air stream and have enough momentum to continue through the stationary air to collide with the lung surface.

Particles that can reach the lung have aerodynamic diameters between 0.5 µm and 5-6 µm (1 µm is 1 micro-meter or about 0.00004 inches). Particles that are larger than 6 µm will leave the air stream and hit the back of your mouth and throat; smaller than 0.5 µm wouldn’t have the ability to reach the lungs and would simply get exhaled.

“The average Technosphere particle is about 2-2.5 µm which is in the middle of the respirable range,” explains Marshall Grant, PhD, MSc, Executive Director, Clinical Pharmacology & Research for MannKind Corporation. “The particle size distribution is a major reason Technosphere powders are highly efficient in delivering drug to the lungs than other dry powder inhalers (DPIs).”

The Technosphere particles in FDA-approved Afrezza® (insulin human) Inhalation Powder and Tyvaso DPI™ (treprostinil) Inhalation Powder are manufactured by different processes and possess different characteristics. But both are made up of small crystals of FDKP (fumaryl diketopiperazine), MannKind’s proprietary molecule. FDKP provides high solubility and fast dissolution at physiologic pH – and more importantly – can crystallize and form particles in the range appropriate for optimum delivery to the lungs.

When Technosphere powder reaches the lung surface, the FDKP and drug dissolve. The FDKP is then rapidly cleared from the lung into systemic circulation. The FDKP is not metabolized, but rather excreted primarily in the urine. Another value of Technosphere powders has been their versatility – they are compatible with a wide range of doses with different types of drugs.

MannKind’s Technosphere powders are delivered into the lung’s airstream via an inhalation device or DPI (dry powder inhaler). The breath-powered inhalers (Dreamboat® being the most common version) provide excellent delivery efficiency and are proven to deliver up to 70% of the dry-powder dose deep into the lungs. Our DPI are designed to be simple, easy to use and discreet. For patients, imagine having a drug in the convenient form of an inhaler that fits in the palm of your hand. This approach allows patients to not only take control of their health but do it while going about their day and enjoying life more humann.

picture 1

NTM Lung Disease on the Rise

“I cough every morning upon waking, so I don’t feel rested.” “Imagine not being able to breathe.” “Anxiety ruins everything about you – it’s not a normal life.” “You just exist from day to day and week to week.” These are a sampling of comments about the most bothersome symptoms from living with Nontuberculous Mycobacteria (NTM) shared in a study from NTM Info & Research, Inc. The statements are unfortunately typical and those with NTM often have unpredictable day-to-day health functioning and reduced quality of life.

NTM lung disease is a serious infection that is caused by bacteria that are common in the environment and can cause lung damage. The reality is that we are all exposed to these bacteria in our day-to-day lives – more than 120 species of mycobacteria have been identified. These common bacteria exist in water and soil particles that are in the air, wet places like hot tubs, steamy bathrooms, dishwashers, and even the dewy ground we walk on at the park. But not everyone is at risk of getting NTM lung disease just because they are exposed.

Those predisposed often have underlying conditions such as asthma, COPD, and bronchiectasis, which makes them prone to NTM infection. NTM is not considered to be contagious. Women over the age of 65 make up the majority of those impacted, with a predominance in those of Caucasian and Asian descent.

A rare disease, NTM can often be difficult to diagnose. Many will experience coughing, fatigue, weight loss and shortness of breath – all of which are common with other lung disease symptoms and other conditions like tuberculosis. With NTM, symptoms often worsen, and that is a marker not to be ignored.

It is estimated that some 86,000 individuals are living with NTM lung diseases, and it is on the rise growing 8% each year. Coastal regions including Gulf States have higher rates of infection accounting for 70% of annual NTM cases.

While no cure is available, treatments to manage NTM are available. Treatment for NTM involves antibiotic and multidrug regimens with duration lasting from months to years with tolerability and adverse reactions to treatment which often leads to a lack of adherence to therapy.

There is a valuable need to develop medicines that are well tolerated and effective that lends to consistent patient use and alleviates symptoms of NTM lung disease. MannKind continues to progress MNKD-101 (Clofazimine) for the treatment of NTM.

picture 1

Release Details

MannKind Corporation Reports 2012 Third Quarter Financial Results

11/01/12
MannKind Corporation Reports 2012 Third Quarter Financial Results

VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 1, 2012-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter ended September 30, 2012.

For the third quarter of 2012, total operating expenses were $35.5 million compared to $32.8 million for the third quarter of 2011, an increase of $2.7 million. Research and development (R&D) expenses were $25.4 million for the third quarter of 2012 compared to $23.1 million for the same quarter in 2011, an increase of $2.3 million. This 10.0% increase was primarily due to an increase of $7.0 million in clinical trial-related activities in the third quarter of 2012, offset in part by a non-recurring $4.1 million expense recorded in the third quarter of 2011 in connection with the settlement of the terminated insulin supply agreement. General and administrative (G&A) expenses were $10.1 million for the third quarter of 2012 compared to $9.6 million for the same quarter of 2011, an increase of $0.5 million. This 5.2% increase in G&A expense was primarily due to an increase in the litigation settlement accrual recorded in the third quarter of 2012.

For the first nine months of 2012, operating expenses totaled $113.5 million compared to $110.0 million in the first nine months of 2011, an increase of $3.5 million. Total R&D expenses were $76.2 million for the first nine months of 2012 compared to $79.7 million in the same period in 2011, a decrease of $3.5 million. This 4.4% decrease was primarily due to a non-recurring $16.0 million expense recorded during the first nine months of 2011 in connection with the settlement of the terminated insulin supply agreement and decreased salary-related expenses of $7.9 million resulting from the February 2011 restructuring, offset by $20.2 million in increased clinical trial-related expenses in the first nine months of 2012. G&A expenses were $37.3 million for the first nine months of 2012 as compared to $30.3 million in the same period in 2011, an increase of $7.0 million. This 23.1% increase was primarily due to the $8.6 million litigation settlement accrual recorded in the first nine months of 2012, partially offset by decreased salary-related costs as a result of the February 2011 reduction in force.

The net loss applicable to common stockholders for the third quarter of 2012 was $42.8 million, or $0.22 per share based on 190.5 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $38.4 million, or $0.31 per share based on 122.1 million weighted average shares outstanding, for the third quarter of 2011. The number of common shares outstanding at September 30, 2012 was 199,767,463.

Cash and short-term investments were $3.2 million at December 31, 2011 and $2.1 million at September 30, 2012, not including total net proceeds of $86.0 million from the underwritten public offering of common stock and warrants in October 2012.

Conference Call

MannKind management will host a conference call to discuss these results today at 6:00 p.m. Eastern Time. To participate in the call please dial 800-447-0521 or 847-413-3238 and use the participant passcode: 33432275. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The website replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing 888-843-7419 or 630-652-3042 and use the participant passcode: 3343 2275#.

Presenting from the Company will be:

  • Chairman and Chief Executive Officer Alfred Mann
  • President and Chief Operating Officer Hakan Edstrom
  • Corporate Vice President and Chief Financial Officer Matthew Pfeffer

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of AFREZZA, competition from other pharmaceutical or biotechnology companies, MannKind’s ability to enter into any collaborations or strategic partnerships, intellectual property matters, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2011 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

                 

MannKind Corporation

(A Development Stage Company)

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share amounts)

 

 

Three months ended

September 30,

Nine months ended

September 30,

Cumulative period

from February 14, 1991

(date of inception)

to September 30,

2012     2011 2012     2011 2012
 
Revenue $ 35   $ —   $ 35   $ 50   $ 3,166  
Operating expenses:
Research and development 25,453 23,132 76,247 79,717 1,442,298
General and administrative 10,069 9,641 37,262 30,293 417,493
In-process research and development costs — — — — 19,726
Goodwill impairment   —     —     —     —     151,428  

Total operating expenses

  35,522     32,773     113,509     110,010     2,030,945  
Loss from operations (35,487 ) (32,773 ) (113,474 ) (109,960 ) (2,027,779 )
Other income (expense) (2,651 ) 79 12,078 1,476 11,002
Interest expense on note payable to related party (2,245 ) (2,863 ) (8,321 ) (7,849 ) (36,655 )
Interest expense on senior convertible notes (2,859 ) (2,845 ) (8,278 ) (8,092 ) (37,072 )
Interest income   —     —     2     18     36,991  
Loss before provision for income taxes (43,242 ) (38,402 ) (117,993 ) (124,407 ) (2,053,513 )
Income tax benefit   (408 )   —     (408 )   —     (382 )
Net loss (42,834 ) (38,402 ) (117,585 ) (124,407 ) (2,053,131 )
Deemed dividend related to beneficial conversion feature of convertible preferred stock — — — — (22,260 )
Accretion on redeemable preferred stock   —     —     —     —     (952 )
Net loss applicable to common stockholders $ (42,834 ) $ (38,402 ) $ (117,585 ) $ (124,407 ) $ (2,076,343 )
Net loss per share applicable to common stockholders — basic and diluted $ (0.22 ) $ (0.31 ) $ (0.71 ) $ (1.02 )
Shares used to compute basic and diluted net loss per share applicable to common stockholders   190,534     122,130     164,611     121,636  
 
 

                     

MannKind Corporation

(A Development Stage Company)

Condensed Consolidated Balance Sheet

(Unaudited)

(in thousands)

 

 

September 30, 2012

December 31, 2011

Assets
Current assets:
Cash and cash equivalents $ 1,765 $ 2,681
Available for sale securities and certificate of deposit 350 515
Prepaid expenses and other current assets   21,082     2,625  
Total current assets 23,197 5,821
Property and equipment — net 186,611 193,029
State research and development credit exchange receivable — net of current portion 293 473
Other assets   230     230  
Total $ 210,331   $ 199,553  
 

Liabilities and Stockholders’ Deficit

Current liabilities $ 51,764 $ 25,360
Senior convertible notes 211,673 210,642
Note payable to principal stockholder 223,142 277,203
Stockholders’ deficit   (276,248 )   (313,652 )
Total $ 210,331   $ 199,553  

Source: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com